Yiu Z Z N, Madan V, Griffiths C E M
Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Clin Exp Dermatol. 2015 Jun;40(4):383-6. doi: 10.1111/ced.12540. Epub 2014 Dec 26.
Acne conglobata (AC) is a chronic, severe, inflammatory variant of acne characterized by development of cystic nodules, abscesses and sinus tracts. AC may prove resistant to conventional acne therapy. The off-label use of adalimumab for the treatment of AC has been reported recently. We present a 26-year-old man with AC resistant to conventional treatment, who was treated with 40 mg adalimumab every other week, with significant clinical improvement. We review the evidence for the use of tumour necrosis factor antagonists in AC and related conditions. This case provides further evidence supporting the role of adalimumab in the treatment of AC.
聚合性痤疮（AC）是痤疮的一种慢性、重度炎症变体，其特征为出现囊性结节、脓肿和窦道。AC可能对传统痤疮治疗有抵抗性。最近有报道称阿达木单抗可用于AC的非适应证治疗。我们报告了一名26岁的男性，其AC对传统治疗有抵抗性，接受每两周一次40mg阿达木单抗治疗后临床症状显著改善。我们回顾了肿瘤坏死因子拮抗剂在AC及相关病症中应用的证据。该病例提供了进一步证据支持阿达木单抗在AC治疗中的作用。
